Navigation Links
Dartmouth researchers test safety of Nivolumab in kidney cancer
Date:6/3/2013

(Lebanon, NH, 5/24/13) Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma (mRCC) at the ASCO Annual Meeting on June 3, 2013.

Metastatic renal cell carcinoma or kidney cancer is the seventh most common cancer, leading to approximately 116,000 deaths annually worldwide. In roughly one-quarter of those with mRCC, the cancer has already spread or metastasized at diagnosis.

Nivolumab is an immune checkpoint inhibitor being tested in many cancers such as advanced melanoma and nonsmall cell lung cancer. It helps the body fight renegade cancer cells by restoring normal T-cell antitumor function. T-cells are a type of white blood cell that act like soldiers by searching out and destroying invaders. Nivolumab accomplishes this by suppressing an immune checkpoint modulator.

In this study, Nivolumab will be used in combination with sunitinib, pazopanib (existing treatments), or ipilimumab. These existing treatments have shown to reduce progression of the disease, but without lasting or durable response. Many patients eventually develop resistance to them. In other Phase 1 and 2 clinical trials, Nivolumab has shown durable responses in patients with mRCC.

The ASCO poster session describes an ongoing four-arm Phase 1 dose-escalation and expansion study evaluating combinations of Nivolumab with sunitinib, pazopanib, or ipilimumab in patients with mRCC. The primary objectives are to assess safety and tolerability, and to determine the recommended Phase 2 dose in patients with mRCC. The secondary objective is to assess preliminary antitumor activity. Researchers will also evaluate overall survival, pharmacodynamics, predictive biomarkers for the combinations, pharmacokinetics and immunogenicity of Nivolumab.


'/>"/>

Contact: Donna Dubuc
donna.m.dubuc@hitchcock.org
603-653-3615
Dartmouth-Hitchcock Medical Center
Source:Eurekalert

Page: 1

Related medicine news :

1. Dartmouth researchers investigate the cognitive effects of athlete head impacts
2. Mayo Clinic, Dartmouth-Hitchcock announce collaboration
3. Dartmouth medical research closes in on new tuberculosis vaccine
4. Leap in leukemia treatment reported by Dartmouth researchers
5. NIH awards $20 million over 5 years to train next generation of global health researchers
6. Researchers develop a new cell and animal model of inflammatory breast cancer
7. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
8. Researchers Find Gene Mutations That May Be a Key to Autism
9. Researchers find evidence of banned antibiotics in poultry products
10. NJ stroke researchers report advances in spatial neglect research at AAN Conference
11. Autism by the numbers: Yale researchers examine impact of new diagnostic criteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 13, 2017 , ... While it’s often important to take certain medications during ... Austin, Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP ... such, it eliminates the need to turn on a light when taking medication during ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... established the certification process to promote standards of excellence for the field of ... scheduled for March 22 – 25, 2018 in Orlando, Florida at the Omni ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... 2017 , ... Apple Rehab Shelton Lakes , which specializes in the ... facility as part of a disaster drill on October 3rd. , Apple Rehab participated ... Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid Plan ...
(Date:10/13/2017)... ... 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is ... vendors and unique items from across the nation, this holiday-themed event will raise funds ... by the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
Breaking Medicine Technology: